JPH Income Statement - TTM - Jerusalem Pharmaceuticals Co. Ltd.

Income Statement (TTM)

Jerusalem Pharmaceuticals Co. Ltd. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000,000 except per share units.

	2020 09-30	2020 12-31	2021 03-31	2021 06-30	2021 09-30	2021 12-31	2022 03-31	2022 06-30	2022 09-30	2022 12-31	2023 03-31	2023 06-30	2023 09-30	2023 12-31	2024 03-31	2024 06-30	2024 09-30	2024 12-31	2025 03-31	2025 06-30
Revenue	36	36	37	40	41	46	47	47	46	46	45	44	43	40	38	38	37	40	42	44
Change (%)		0.00	2.45	6.24	4.15	12.03	2.64	-0.35	-2.19	-0.22	-2.34	-2.41	-1.92	-8.06	-3.78	-1.70	-0.15	6.34	5.19	5.53
% of Revenue	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00

Cost Of Sales	19	20	21	21	23	23	23	23	22	23	22	21	19	18	18	18	19	20	20	21
Change (%)		4.01	3.23	2.55	8.09	1.00	-0.66	-2.74	-3.46	5.22	-3.49	-5.27	-8.81	-4.51	-1.40	-1.15	5.23	4.90	2.65	2.03
% of Revenue	53.57	55.72	56.14	54.19	56.24	50.70	49.08	47.90	47.28	49.85	49.26	47.82	44.47	46.18	47.33	47.59	50.16	49.48	48.28	46.68

Gross Operating Profit	17	16	16	18	18	23	24	25	24	23	23	23	24	21	20	20	19	20	22	24
Change (%)		-4.63	1.47	10.97	-0.52	26.20	6.02	1.96	-1.02	-5.09	-1.19	0.35	4.39	-10.90	-5.83	-2.21	-5.04	7.79	7.68	8.79
% of Revenue	46.43	44.28	43.86	45.81	43.76	49.30	50.92	52.10	52.72	50.15	50.74	52.18	55.53	53.82	52.67	52.41	49.84	50.52	51.72	53.32

SG&A	11	11	11	12	12	13	13	13	13	13	12	12	13	12	12	12	12	12	12	13
Change (%)		-2.12	6.34	9.07	-5.88	12.09	0.48	0.59	-2.84	0.79	-3.01	-2.52	3.37	-7.89	2.29	-1.71	5.17	1.11	0.93	4.29
% of Revenue	29.81	29.18	30.29	31.09	28.10	28.12	27.53	27.79	27.60	27.88	27.69	27.66	29.15	29.21	31.05	31.05	32.70	31.09	29.83	29.48

R&D	1	1	1	2	2	2	2	2	2	2	2	2	2	1	1	0	0	1	1	1
Change (%)		43.79	2.48	17.05	2.61	2.96	12.03	0.26	2.71	-14.05	10.03	-7.52	-4.13	-44.77	-37.14	-24.36	-3.91	163.87	2.12	-1.37
% of Revenue	2.63	3.78	3.78	4.17	4.10	3.77	4.12	4.14	4.35	3.75	4.22	4.00	3.91	2.35	1.53	1.18	1.14	2.82	2.74	2.56

OpEx	31	32	34	36	36	38	39	37	36	37	36	34	33	31	30	30	31	33	34	35
Change (%)		3.79	4.03	5.44	2.73	4.82	0.90	-2.88	-2.99	2.67	-3.33	-4.44	-4.87	-6.51	-0.72	-0.51	3.58	5.56	2.07	2.65
% of Revenue	85.73	88.98	90.35	89.66	88.44	82.75	81.34	79.28	78.63	80.91	80.09	78.43	76.07	77.35	79.80	80.77	83.79	83.17	80.70	78.50

Operating Income	5	4	4	4	5	8	9	10	10	9	9	9	10	9	8	7	6	7	8	10
Change (%)		-22.78	-10.29	13.81	16.48	67.18	10.98	10.68	0.87	-10.86	1.88	5.72	8.80	-12.98	-14.21	-6.42	-15.80	10.39	20.61	17.58
% of Revenue	14.27	11.02	9.65	10.34	11.56	17.25	18.66	20.72	21.37	19.09	19.91	21.57	23.93	22.65	20.20	19.23	16.21	16.83	19.30	21.50

Interest Expense	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Change (%)		-36.33	22.43	-25.02	0.88	9.58	13.31	29.57	-13.82	-19.10	-4.53	-18.52	21.08	-26.21	88.79	18.02	22.12	-81.69
% of Revenue	-0.24	-0.16	-0.19	-0.13	-0.13	-0.12	-0.14	-0.18	-0.16	-0.13	-0.12	-0.10	-0.13	-0.10	-0.20	-0.24	-0.30	-0.05

Net Income	5	4	3	4	4	7	7	8	8	7	7	8	8	7	6	5	4	5	7	8
Change (%)		-25.53	-9.82	13.64	11.73	54.69	6.84	10.84	-1.01	-7.24	2.33	4.99	9.88	-17.86	-17.37	-9.37	-21.06	22.50	36.29	12.61
% of Revenue	13.74	10.23	9.01	9.64	10.34	14.27	14.86	16.52	16.72	15.55	16.29	17.53	19.64	17.54	15.07	13.89	10.98	12.65	16.39	17.49

Source: Capital IQ

Jerusalem Pharmaceuticals Co. Ltd. - Income Statement (TTM)

Income Statement (TTM)